Sygnature Discovery invests £3m to expand high-throughput screening and translational oncology capabilities Kumar Jeetendra | December 16, 2020 Nottingham and Alderley Park, UK – 16th December 2020 – Life Science Newswire – Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical contract research organization, is strengthening its high-throughput screening (HTS) and translational oncology service-offerings by investing £3 million in new instrumentation and equipment. Sygnature’s Translational Oncology department at Alderley Park is currently …
